Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01988961 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 103
- Enrollment target
NCT01988961 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 103 participants.
The verdict
NCT01988961, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 103 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the accuracy of a subset of the length-109 probe set panel (a genetic test) in predicting response to golimumab treatment in participants with moderately to severely active ulcerative colitis (UC).
Interventions
- BIOLOGICAL Golimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2013-12 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01988961
The ClinicalTrials.gov registry entry for NCT01988961 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Golimumab is the first listed.
NCT01988961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01988961 about?
NCT01988961 is a clinical study titled "A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis". The purpose of this study is to evaluate the accuracy of a subset of the length-109 probe set panel (a genetic test) in predicting response to golimumab treatment in participants with moderately to severely active ulcerative colitis (UC).
What is the current status of trial NCT01988961?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2013-12. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01988961?
The interventions under investigation include: Golimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01988961?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.